The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients

Dan Painter; Alexandra Smith; Ruth de Tute; Simon Crouch; Eve Roman; Andrew Jack

doi:10.1111/bjh.13412

The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients

Dan Painter, Alexandra Smith, Ruth de Tute, Simon Crouch, Eve Roman, Andrew Jack

Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

This study investigates the value of performing a staging bone marrow in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and classical hodgkin lymphoma (CHL). The results of 3112 staging bone marrow examinations were assessed for impact on prognostic assessment and critical treatment decisions. The detection of marrow involvement altered the disease-specific prognostic index for 4·3% of DLBCL, 6·2% of FL and 0·6% of CHL but marrow involvement in DLBCL was an independent prognostic factor. Knowing the marrow status potentially changed treatment in 92 patients, detection of these patients would have required 854 examinations to be performed.

Original language	English
Journal	British Journal of Haematology
Early online date	29 Apr 2015
DOIs	https://doi.org/10.1111/bjh.13412
Publication status	Published - Apr 2015

Bibliographical note

Access to Document

10.1111/bjh.13412

Cite this

@article{5c95b9c37f904bdbb50a7e2d1795b02f,

title = "The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients",

abstract = "This study investigates the value of performing a staging bone marrow in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and classical hodgkin lymphoma (CHL). The results of 3112 staging bone marrow examinations were assessed for impact on prognostic assessment and critical treatment decisions. The detection of marrow involvement altered the disease-specific prognostic index for 4·3% of DLBCL, 6·2% of FL and 0·6% of CHL but marrow involvement in DLBCL was an independent prognostic factor. Knowing the marrow status potentially changed treatment in 92 patients, detection of these patients would have required 854 examinations to be performed.",

author = "Dan Painter and Alexandra Smith and {de Tute}, Ruth and Simon Crouch and Eve Roman and Andrew Jack",

note = "{\textcopyright} 2015 John Wiley & Sons Ltd.",

year = "2015",

month = apr,

doi = "10.1111/bjh.13412",

language = "English",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients

AU - Painter, Dan

AU - Smith, Alexandra

AU - de Tute, Ruth

AU - Crouch, Simon

AU - Roman, Eve

AU - Jack, Andrew

PY - 2015/4

Y1 - 2015/4

N2 - This study investigates the value of performing a staging bone marrow in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and classical hodgkin lymphoma (CHL). The results of 3112 staging bone marrow examinations were assessed for impact on prognostic assessment and critical treatment decisions. The detection of marrow involvement altered the disease-specific prognostic index for 4·3% of DLBCL, 6·2% of FL and 0·6% of CHL but marrow involvement in DLBCL was an independent prognostic factor. Knowing the marrow status potentially changed treatment in 92 patients, detection of these patients would have required 854 examinations to be performed.

AB - This study investigates the value of performing a staging bone marrow in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and classical hodgkin lymphoma (CHL). The results of 3112 staging bone marrow examinations were assessed for impact on prognostic assessment and critical treatment decisions. The detection of marrow involvement altered the disease-specific prognostic index for 4·3% of DLBCL, 6·2% of FL and 0·6% of CHL but marrow involvement in DLBCL was an independent prognostic factor. Knowing the marrow status potentially changed treatment in 92 patients, detection of these patients would have required 854 examinations to be performed.

U2 - 10.1111/bjh.13412

DO - 10.1111/bjh.13412

M3 - Article

C2 - 25920510

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -